Diamond in the Rough With good Risk to Reward
Tetra Bio has just received 2 DIN from Health Canada for TERPACAN™ (hemorrhoids) & TERPACAN™ (back & muscle pain) with plans of these hitting Pharmacy Retail outlets for Mid 2020. Markets for these 2 drugs are 22mil and 432mil as of 2019.
They also just did a bought deal with Echelon for gross proceeds of 10mil giving them Cash on had to bring Terpacan products to market expected close date of Feb 13, 2020. Now the big catalyst up coming is the potential of FDA AA designation for the drug QIXLEEF (PPP001) which they received a Favorable letter of advice on Jan 13, 2020 and they anticipate to hear back from FDA on the AA by end of Jan 2020, this drug is for advance pain management in Cancer and they also have plans to develop QIXLEEF for pain indications beyond cancer.
Allied Market Research (reference), the global drug market for pain management was about $60 billion in 2016 and is estimated to reach $130 billion by 2023. This includes pain medications for indications such as Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia. With this all in mind the stock price just bounced off the .46 support zone back to the .50 support zone and anticipate next week to start the climb back up towards .66 - .70 to close out the gap that was made from the Bought Deal for a potential gain of 40% and with a potential of retesting the .46 support zone or loss of -8%.
Based off if FDA is positive we could see a retrace of $1.21 to $1.63+ or 230%+ and a draw back if not good of potential of retest of .33 or a loss of -31%. All and all I Find this Company a strong buy Fundamentally and Technically with the supports holding and DEMA 11/22 cross along with the A/D above EMA I would look at an entry of .50 - .53 this coming week.
They also just did a bought deal with Echelon for gross proceeds of 10mil giving them Cash on had to bring Terpacan products to market expected close date of Feb 13, 2020. Now the big catalyst up coming is the potential of FDA AA designation for the drug QIXLEEF (PPP001) which they received a Favorable letter of advice on Jan 13, 2020 and they anticipate to hear back from FDA on the AA by end of Jan 2020, this drug is for advance pain management in Cancer and they also have plans to develop QIXLEEF for pain indications beyond cancer.
Allied Market Research (reference), the global drug market for pain management was about $60 billion in 2016 and is estimated to reach $130 billion by 2023. This includes pain medications for indications such as Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia. With this all in mind the stock price just bounced off the .46 support zone back to the .50 support zone and anticipate next week to start the climb back up towards .66 - .70 to close out the gap that was made from the Bought Deal for a potential gain of 40% and with a potential of retesting the .46 support zone or loss of -8%.
Based off if FDA is positive we could see a retrace of $1.21 to $1.63+ or 230%+ and a draw back if not good of potential of retest of .33 or a loss of -31%. All and all I Find this Company a strong buy Fundamentally and Technically with the supports holding and DEMA 11/22 cross along with the A/D above EMA I would look at an entry of .50 - .53 this coming week.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.